Home › Companies › DFTX

Definium Therapeutics, Inc.

DFTX Lead: Phase 3 4 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (4 active programs)

DT120 ODT

lysergide tartrate · DT120

Small Molecule Target: 5-HT2A

Generalized Anxiety Disorder Phase 3 oral
Major Depressive Disorder Phase 3 oral
Posttraumatic Stress Disorder Phase 3 oral

R(-)-MDMA

DT402

Autism Spectrum Disorder Phase 2

Biotech Distilled coverage (4)

2026-05-08 UPDATE: Definium (DFTX) - The Pre-Readout Setup Locks In, PTSD Joins the Party 🔒 Paid
2026-04-27 UPDATE: Definium (DFTX) - The DEA Cloud Lifts and the Stats Get Sharper 🔒 Paid
2026-02-28 UPDATE: Definium (DFTX) Q4 Financial Update 🔒 Paid
2026-01-14 Definium Therapeutics, formerly MindMed (DFTX, formerly MNMD): Scientific Deep Dive for DT120 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.